

Atty Dkt No. 7011-0032
USSN: 09/501,328
PATENT

AMENDMENT

In the Specification:

Please delete the sentence beginning at line 26 of page 33 and replace it with the following.

A₁₃
Various combinations of these ten resulting *M. tuberculosis* antigen recombinant WRG7054 plasmid constructs were used to form cocktail compositions for the vaccination study.

Please delete the sentence beginning at line 28 of page 33 and replace it with the following.

A₁₄
M. tuberculosis H37Rv and *M. bovis* BCG Pasteur cultures (Copenhagen 1331) were obtained from a commercial source, grown to early mid-log phase, and aliquots were stored at -70°C until used.

In the Claims:

✓✓✓✓✓✓✓✓
Please delete claims 9, 12, 17, 20, 31, 34, 43 and 46 without prejudice and disclaimer.

✓✓✓✓✓✓✓✓
Please amend claims 7, 10-11, 13, 15, 18-19, 21, 25-26, 32-33, 35, 37, 44-45 and 47 as follows.

A¹
7. (Amended) A method for eliciting an immune response against *M. tuberculosis* in a subject, said method comprising:

(a) obtaining a vector construct that has inserted therein a recombinant polynucleotide containing a plurality of *Mycobacterium*

Atty Dkt No. 7011-0032

USSN: 09/501,328

PATENT

tuberculosis antigens operably linked to control sequences suitable for expression in the subject; and

(b) administering said vector construct to the subject whereby said antigens are expressed in the subject at sufficient levels to elicit an immune response.

A²

10. (Amended) The method of claim 8, wherein the secondary composition comprises at least one culture filtrate protein antigen of *M. tuberculosis*.

11. (Amended) The method of claim 8, wherein the secondary composition comprises at least one isolated subunit of a *M. tuberculosis* protein.

A³

13. (Amended) The method of claim 8, wherein the secondary composition comprises a live attenuated vaccine derived from a *Mycobacterium* species.

15. (Amended) A method for eliciting an immune response against *M. tuberculosis* in a subject, said method comprising:

A⁴

(a) obtaining a composition containing a plurality of recombinant polynucleotides each comprising a sequence encoding a *Mycobacterium tuberculosis* antigen operably linked to control sequences suitable for expression in the subject; and

(b) administering the composition to the subject whereby each said antigen is expressed in the subject at sufficient levels to elicit an immune response.

Atty Dkt No. 7011-0032
USSN: 09/501,328
PATENT

A5
18. (Amended) The method of claim 16, wherein the secondary composition comprises at least one culture filtrate protein antigen of *M. tuberculosis*.

19. (Amended) The method of claim 16, wherein the secondary composition comprises at least one isolated subunit of a *M. tuberculosis* protein.

A6
21. (Amended) The method of claim 16, wherein the secondary composition comprises a live attenuated vaccine derived from a *Mycobacterium* species.

25. (Amended) A method for eliciting an immune response to *M. tuberculosis* in a subject, said method comprising:

A7
(a) providing a core carrier coated with a vector construct that has inserted therein a recombinant polynucleotide containing a plurality of *Mycobacterium tuberculosis* antigens operably linked to control sequences suitable for expression in the subject; and

(b) administering the coated core carrier to the subject using a particle-mediated delivery technique, wherein the *M. tuberculosis* antigens are expressed in the subject at sufficient levels to elicit an immune response.

26. (Amended) The method of claim 25, wherein [the core carrier has an average diameter of about 0.5 to about 5 μ m and a density sufficient to allow delivery into the subject.

A8
32. (Amended) The method of claim 30, wherein the secondary composition comprises at least one culture filtrate protein antigen of *M. tuberculosis*.

Atty Dkt No. 7011-0032
USSN: 09/501,328
PATENT

33. (Amended) The method of claim 30, wherein the secondary composition comprises at least one isolated subunit of a *M. tuberculosis* protein.

A⁹
35. (Amended) The method of claim 30, wherein the secondary composition comprises a live attenuated vaccine derived from a *Mycobacterium* species.

37. (Amended) A method for eliciting an immune response to *M. tuberculosis* in a subject, said method comprising:

A¹⁰
(a) providing a core carrier coated with a composition containing a plurality of recombinant polynucleotides each comprising a sequence encoding a *Mycobacterium tuberculosis* antigen operably linked to control sequences suitable for expression in the subject; and

(b) administering the coated core carrier to the subject using a particle-mediated delivery technique, wherein the *M. tuberculosis* antigens are expressed in the subject at sufficient levels to elicit an immune response.

A¹¹
44. (Amended) The method of claim 42, wherein the secondary composition comprises at least one culture filtrate protein antigen of *M. tuberculosis*.

45. (Amended) The method of claim 42, wherein the secondary composition comprises at least one isolated subunit of a *M. tuberculosis* protein.

A¹²
47. (Amended) The method of claim 42, wherein the secondary composition comprises a live attenuated vaccine derived from a *Mycobacterium* species.